<p>Anti-Topo I: anti-topoisomerase I antibodies; ACA: anti-centromere antibodies; ILD interstitial lung disease. Data are expressed as % or mean ± SD. SSc systemic sclerosis. ILD Interstitial lung disease.</p
To evaluate clinical associations of anti-PM/Scl antibodies in patients with SSc in a multicentre in...
To evaluate clinical associations of anti-PM/Scl antibodies in patients with Systemic Sclerosis (SSc...
Objectives To characterize patients with positive anti-topoisomerase I (ATA) in lcSSc. Methods SSc p...
Objectives The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) ...
Objectives The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) ...
Objectives The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) ...
Objectives: The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD)...
Objectives: The prevalence and characteristics of systemic sclerosis-associated interstitial lung di...
Objectives: The prevalence and characteristics of systemic sclerosis-associated interstitial lung di...
<p>ACA, anticentromere antibodies; ANA, antinuclear antibodies; Anti-Scl70, anti-Scl70 antibodies; C...
OBJECTIVES: The prevalence and characteristics of systemic sclerosis-associated interstitial lung di...
OBJECTIVES: The prevalence and characteristics of systemic sclerosis-associated interstitial lung di...
OBJECTIVES: The prevalence and characteristics of systemic sclerosis-associated interstitial lung di...
OBJECTIVES: The prevalence and characteristics of systemic sclerosis-associated interstitial lung di...
To evaluate clinical associations of anti-PM/Scl antibodies in patients with SSc in a multicentre in...
To evaluate clinical associations of anti-PM/Scl antibodies in patients with SSc in a multicentre in...
To evaluate clinical associations of anti-PM/Scl antibodies in patients with Systemic Sclerosis (SSc...
Objectives To characterize patients with positive anti-topoisomerase I (ATA) in lcSSc. Methods SSc p...
Objectives The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) ...
Objectives The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) ...
Objectives The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) ...
Objectives: The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD)...
Objectives: The prevalence and characteristics of systemic sclerosis-associated interstitial lung di...
Objectives: The prevalence and characteristics of systemic sclerosis-associated interstitial lung di...
<p>ACA, anticentromere antibodies; ANA, antinuclear antibodies; Anti-Scl70, anti-Scl70 antibodies; C...
OBJECTIVES: The prevalence and characteristics of systemic sclerosis-associated interstitial lung di...
OBJECTIVES: The prevalence and characteristics of systemic sclerosis-associated interstitial lung di...
OBJECTIVES: The prevalence and characteristics of systemic sclerosis-associated interstitial lung di...
OBJECTIVES: The prevalence and characteristics of systemic sclerosis-associated interstitial lung di...
To evaluate clinical associations of anti-PM/Scl antibodies in patients with SSc in a multicentre in...
To evaluate clinical associations of anti-PM/Scl antibodies in patients with SSc in a multicentre in...
To evaluate clinical associations of anti-PM/Scl antibodies in patients with Systemic Sclerosis (SSc...
Objectives To characterize patients with positive anti-topoisomerase I (ATA) in lcSSc. Methods SSc p...